Years of research at Israel’s Bar-Ilan University show the efficacy of the T-cell Repertoire as biomarker. We use these repertoire data and proprietary machine learning algorithms to, very effectively, detect cancer. We are now ready to develop diagnostic kits to detect cancer at an early stage:

Available methods for early detection are insufficient and do not provide the needed accuracy. Unlike current technologies, the immune system is able to detect these changes long before they present any clinical manifestation. Clonal aims to deliver a reliable bio-marker map that would do just that.

The TCR repertoire provides a per-patient unique immune code. This code reflects, in real-time, the immune system’s response to stimuli. The TCR repertoire is composed of millions “clones” that make up each person’s individual code.

We have translated these data into health status.